Refine your search

Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Site for A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa: Phase 2 Subject and Investigator Blinded, 68 week study with phone call 20 weeks after last dose. Hidradenitis Suppurativa (HS) is a chronic recurrent and debilitating skin condition that typically presents with deep and painful lesions. The most common areas affected are the armpits, the groin, and the anus and genitals area. The purpose of the study is to find out if risankizumab is beneficial and well tolerated in patients with HS. Each subject will be assigned to 1 of 3 treatment groups, reassigned to a different treatment at week 16, and then receive risankizumab at week 20.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03926169
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Moderate to Severe HS for at least 1 year
HS lesions in at least 2 affected areas
Willing to follow all study instructions
Exclusion Criteria:
Certain treatments for HS are not allowed; coordinator will discuss specific treatments
unable or unwilling to return to the study site for all study visits and tests.
Known Hepatitis B, Hepatitis C, or HIV infections
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA